Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Nelfinavir Mesylate

FDA-approved product (powder, oral), marketed as Viracept.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Nelfinavir Mesylate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • HIV infection
  • HIV-1 infection

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Protease inhibitors
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AE04

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA46.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli42.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae34.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis59.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Nelfinavir Mesylate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Nelfinavir Mesylate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Autophagy Maintenance (AUTOMAIN)

    NCT06971744 · start 2025-12-18

    Registered record
    Registry ID
    NCT06971744
    Conditions
    Ovarian Cancer
    Interventions
    Hydroxychloroquine; Nelfinavir; Bevacizumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-12-18
    Completion
    2029-06-18
    Enrolment
    38

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOvarian Cancer
    InterventionHydroxychloroquine; Nelfinavir; Bevacizumab
    PhasePhase 2
    Registry statusRecruiting

  • Treating Anemia in Myelofibrosis With Repurposed Drugs (Nelfinavir) That Restore Iron Delivery to the Bone Marrow

    NCT07281781 · start 2025-09-16

    Registered record
    Registry ID
    NCT07281781
    Conditions
    Myelofibrosis; Myelofibrosis; Anemia
    Interventions
    Nelfinavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2025-09-16
    Completion
    2027-06
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMyelofibrosis; Myelofibrosis; Anemia
    InterventionNelfinavir
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • A Phase II Single-arm Intervention Trial of Nelfinavir in Patients With Grade 2/3 or 3 Cervical Intraepithelial Neoplasia

    NCT01925378 · start 2018-11-07

    Registered record
    Registry ID
    NCT01925378
    Conditions
    Cervical Dysplasia
    Interventions
    Nelfinavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2018-11-07
    Completion
    2022-12
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCervical Dysplasia
    InterventionNelfinavir
    PhasePhase 2
    Registry statusWithdrawn

  • Radiosensitizing Effect of Nelfinavir in Locally Advanced Carcinoma of Cervix

    NCT03256916 · start 2018-01-16

    Registered record
    Registry ID
    NCT03256916
    Conditions
    Carcinoma Cervix,Stage III
    Interventions
    Nelfinavir; Cisplatin; Pelvic EBRT and Brachytherapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2018-01-16
    Completion
    2024-05-28
    Enrolment
    348

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma Cervix,Stage III
    InterventionNelfinavir; Cisplatin; Pelvic EBRT and Brachytherapy
    PhasePhase 3
    Registry statusCompleted

  • Dose Escalation Study of Nelfinavir Plus MLN9708 in Patients With Advanced Solid Tumors or Lymphoma

    NCT03422874 · start 2016-08

    Registered record
    Registry ID
    NCT03422874
    Conditions
    Neoplasms; Lymphoma
    Interventions
    MLN9708; Nelfinavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Withdrawn
    Start
    2016-08
    Completion
    2017-08-04
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeoplasms; Lymphoma
    InterventionMLN9708; Nelfinavir
    PhasePhase 1
    Registry statusWithdrawn

  • Systemic Therapy and Chemoradiation in Advanced Localised Pancreatic Cancer - 2

    NCT02024009 · start 2016-03

    Registered record
    Registry ID
    NCT02024009
    Conditions
    Pancreatic Neoplasms (Locally Advanced Non-metastatic)
    Interventions
    nab-paclitaxel; 60Gy in 30#; 50.4Gy in 28#; Nelfinavir; Capecitabine; Gemcitabine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2016-03
    Completion
    2021-06-23
    Enrolment
    159

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPancreatic Neoplasms (Locally Advanced Non-metastatic)
    Interventionnab-paclitaxel; 60Gy in 30#; 50.4Gy in 28#; Nelfinavir +2 more
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer

    NCT01959672 · start 2013-09-06

    Registered record
    Registry ID
    NCT01959672
    Conditions
    Pancreatic Adenocarcinoma; Resectable Pancreatic Carcinoma; Stage I Pancreatic Cancer; Stage IA Pancreatic Cancer; Stage IB Pancreatic Cancer; Stage II Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer; Stage III Pancreatic Cancer
    Interventions
    4-Dimensional Computed Tomography; Fluorouracil; Gemcitabine Hydrochloride; Laboratory Biomarker Analysis; Leucovorin Calcium; Nelfinavir Mesylate; Oregovomab; Stereotactic Body Radiation Therapy; Therapeutic Conventional Surgery
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2013-09-06
    Completion
    2018-12-01
    Enrolment
    11

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPancreatic Adenocarcinoma; Resectable Pancreatic Carcinoma; Stage I Pancreatic Cancer; Stage IA Pancreatic Cancer +5 more
    Intervention4-Dimensional Computed Tomography; Fluorouracil; Gemcitabine Hydrochloride; Laboratory Biomarker Analysis +5 more
    PhasePhase 2
    Registry statusCompleted

  • Radical Lung Radiotherapy Plus Nelfinavir

    NCT01447589 · start 2012-02

    Registered record
    Registry ID
    NCT01447589
    Conditions
    Lung Cancer
    Interventions
    nelfinavir; Radical Radiotherapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Withdrawn
    Start
    2012-02
    Completion
    2012-10
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLung Cancer
    Interventionnelfinavir; Radical Radiotherapy
    PhasePhase 1 / Phase 2
    Registry statusWithdrawn

  • Nelfinavir Mesylate and Bortezomib in Treating Patients With Relapsed or Progressive Advanced Hematologic Cancer

    NCT01164709 · start 2010-07

    Registered record
    Registry ID
    NCT01164709
    Conditions
    Leukemia; Lymphoma; Mature T-cell and Nk-cell Neoplasms; Multiple Myeloma and Plasma Cell Neoplasm
    Interventions
    bortezomib; nelfinavir mesylate
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-07
    Completion
    2013-11
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLeukemia; Lymphoma; Mature T-cell and Nk-cell Neoplasms; Multiple Myeloma and Plasma Cell Neoplasm
    Interventionbortezomib; nelfinavir mesylate
    PhasePhase 1
    Registry statusCompleted

  • Study of Nelfinavir and Temsirolimus in Patients With Advanced Cancers

    NCT01079286 · start 2009-06

    Registered record
    Registry ID
    NCT01079286
    Conditions
    Renal Cell Cancer; Cancer
    Interventions
    Nelfinavir and temsirolimus
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2009-06
    Completion
    2011-08
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRenal Cell Cancer; Cancer
    InterventionNelfinavir and temsirolimus
    PhasePhase 1
    Registry statusCompleted

  • Nelfinavir, a Phase I/Phase II Rectal Cancer Study

    NCT00704600 · start 2008-09

    Registered record
    Registry ID
    NCT00704600
    Conditions
    Colorectal Cancer; Colorectal Carcinoma; Colorectal Tumors; Neoplasms, Colorectal
    Interventions
    nelfinavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2008-09
    Completion
    2013-07
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Cancer; Colorectal Carcinoma; Colorectal Tumors; Neoplasms, Colorectal
    Interventionnelfinavir
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Study to Evaluate Using Nelfinavir With Chemoradiation for Non-small Cell Lung Cancer

    NCT00791336 · start 2008-08

    Registered record
    Registry ID
    NCT00791336
    Conditions
    Carcinoma, Non-Small-Cell Lung
    Interventions
    Nelfinavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2008-08
    Completion
    2011-03
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma, Non-Small-Cell Lung
    InterventionNelfinavir
    PhasePhase 2
    Registry statusTerminated

  • Clinical Trial of CNS-targeted HAART (CIT2)

    NCT00624195 · start 2007-03

    Registered record
    Registry ID
    NCT00624195
    Conditions
    HIV Infections
    Interventions
    FDA Approved Antiretroviral Therapy (see list below)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2007-03
    Completion
    2012-06
    Enrolment
    59

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionFDA Approved Antiretroviral Therapy (see list below)
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • When to Start Anti-HIV Drugs in Children Infected With HIV (The PREDICT Study)

    NCT00234091 · start 2006-04

    Registered record
    Registry ID
    NCT00234091
    Conditions
    HIV Infections
    Interventions
    Abacavir; Efavirenz; Lamivudine; Lopinavir/Ritonavir; Nelfinavir; Nevirapine; Zidovudine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2006-04
    Completion
    2011-09
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionAbacavir; Efavirenz; Lamivudine; Lopinavir/Ritonavir +3 more
    PhasePhase 3
    Registry statusCompleted

  • Safety Of VIRACEPT® 625mg Administered To HIV-Infected Women During Pregnancy

    NCT00246610 · start 2006-03

    Registered record
    Registry ID
    NCT00246610
    Conditions
    HIV Infection
    Interventions
    Nelfinavir mesylate, 625 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2006-03
    Completion
    2007-11
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infection
    InterventionNelfinavir mesylate, 625 mg
    PhasePhase 4
    Registry statusCompleted